糖尿病性胃不全麻痺治療の世界市場レポート 2024

糖尿病性胃不全麻痺治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.2%の年間複合成長率（CAGR）で47億3,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、精密医療と個別化療法の導入、糖尿病人口の増加、研究開発努力の増加、規制状況の変化に起因すると考えられます。予測期間中に予想される注目すべき動向には、治療における技術革新、新しい治療法の出現、症状管理への焦点、遠隔医療と遠隔モニタリングの利用、腸内マイクロバイオームを標的とした介入などが含まれます。

糖尿病性胃不全麻痺治療市場は、糖尿病の有病率の増加により成長する準備ができています。特定の時期に糖尿病と診断された人口の割合を示す糖尿病の有病率により、糖尿病性胃不全麻痺治療の需要が高まっています。この治療は、糖尿病の一般的な合併症である胃不全麻痺に関連する症状や合併症を管理するために非常に重要です。たとえば、2023年 4月の時点で、英国糖尿病協会は、英国では430万人が糖尿病を抱えており、240万人以上が2型糖尿病の高リスクにあると報告しました。 2021-22年の登録数は148,951件に達し、糖尿病の有病率が糖尿病性胃不全麻痺治療市場に与える重大な影響を強調しています。

糖尿病性胃不全麻痺治療市場の成長は、前糖尿病人口の増加によってさらに加速されています。血糖値が上昇していても糖尿病の診断基準をまだ満たしていない前糖尿病患者は、人口のかなりの部分を占めています。糖尿病と胃不全麻痺を含むその合併症の効果的な予防と治療戦略に重点が置かれていることは明らかです。たとえば、2022年 6月の疾病管理予防センターのデータによると、米国では18歳以上の9,600万人が糖尿病前症を患っており、成人人口の38.0%を占めています。かなりの数の糖尿病前症患者が糖尿病性胃不全麻痺治療市場の成長の主要な原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の糖尿病性胃不全麻痺治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 薬剤
• 手術
• 世界の糖尿病性胃不全麻痺治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 注射剤
• 世界の糖尿病性胃不全麻痺治療市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 代償性胃不全麻痺
• 胃不全
• 世界の糖尿病性胃不全麻痺治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の糖尿病性胃不全麻痺治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 在宅ケア
• 専門クリニック
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の糖尿病性胃不全麻痺治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の糖尿病性胃不全麻痺治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖尿病性胃不全麻痺治療市場の競合情勢
• 糖尿病性胃不全麻痺治療市場の企業プロファイル
  • Cardinal Health Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ipca Laboratories Ltd.
  • Abbott Laboratories

第31章 その他の大手および革新的な企業

• GlaxoSmithKline plc
• AstraZeneca plc
• Medtronics plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Kimberly-Clark Corporation
• Teva Pharmaceutical Industries Ltd.
• Janssen Global Services LLC
• Boston Scientific Corporation
• Fresenius Kabi AG
• Bausch Health Companies Inc.
• Allergan Inc.
• Salix Pharmaceuticals Inc.
• Ironwood Pharmaceuticals Inc.
• Wockhardt Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Diabetic gastroparesis is a condition characterized by damage to the stomach muscles and nerves due to high blood glucose levels, resulting in delayed gastric emptying and associated symptoms. Diabetic gastroparesis treatment involves medical interventions and management strategies aimed at alleviating symptoms and improving the overall well-being of individuals affected by this condition. The treatment approach encompasses various interventions to address delayed stomach emptying and related gastrointestinal symptoms.

The primary treatments for diabetic gastroparesis include medication and surgery. Medications, such as gastroprokinetic agents, antiemetic agents, and botulinum toxin, are utilized for the diagnosis, treatment, prevention, or alleviation of symptoms associated with this medical condition. These medications are administered orally or via injections and are distributed through hospital pharmacies, retail pharmacies, and other channels catering to hospitals, homecare, specialty clinics, and similar healthcare settings.

The diabetic gastroparesis treatment market research report is one of a series of new reports from The Business Research Company that provides diabetic gastroparesis treatment market statistics, including diabetic gastroparesis treatment industry global market size, regional shares, competitors with a diabetic gastroparesis treatment market share, detailed diabetic gastroparesis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic gastroparesis treatment industry. This diabetic gastroparesis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic gastroparesis treatment market size has grown strongly in recent years. It will grow from $3.68 billion in 2023 to $3.86 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth observed in the historical period can be attributed to factors such as the increasing prevalence of diabetes, limited treatment options, a rise in awareness and diagnosis of diabetic gastroparesis, and the development of healthcare infrastructure.

The diabetic gastroparesis treatment market size is expected to see strong growth in the next few years. It will grow to $4.73 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the adoption of precision medicine and personalized therapies, the growing diabetic population, increased research and development efforts, and a shift in the regulatory landscape. Noteworthy trends expected in the forecast period include technological innovations in treatments, the emergence of novel therapies, a focus on symptom management, the utilization of telemedicine and remote monitoring, and interventions targeting the gut microbiome.

The diabetic gastroparesis treatment market is poised for growth, driven by the increasing prevalence of diabetes. The prevalence of diabetes, indicating the percentage of the population diagnosed with diabetes at a specific time, has led to a growing demand for diabetic gastroparesis treatment. This treatment is crucial for managing symptoms and complications associated with gastroparesis, a common complication of diabetes. For example, as of April 2023, The British Diabetic Association reported that 4.3 million individuals in the UK are living with diabetes, with more than 2.4 million at high risk of type 2 diabetes. The registration numbers for 2021-22 reached 148,951, emphasizing the significant impact of diabetes prevalence on the diabetic gastroparesis treatment market.

The growth of the diabetic gastroparesis treatment market is further fueled by the increase in the prediabetic population. Prediabetic individuals, with elevated blood sugar levels not yet meeting the diabetes diagnosis criteria, represent a substantial portion of the population. The emphasis on effective prevention and treatment strategies for diabetes and its complications, including gastroparesis, is evident. For instance, data from the Centers for Disease Control and Prevention in June 2022 revealed that 96 million people aged 18 or older have prediabetes in the United States, constituting 38.0% of the adult population. The significant prediabetic population is a key driver for the growth of the diabetic gastroparesis treatment market.

The diabetic gastroparesis treatment market is anticipated to experience growth due to the rising number of surgical procedures. Surgical interventions in diabetic patients, such as Nissen fundoplication, gastric bypass surgery, and cholecystectomy, can lead to post-surgical gastroparesis. The increase in surgical procedures, as reported by the Aesthetic Society in April 2022, with a 54% rise in surgical aesthetic procedures in 2021 compared to 2020, contributes to the demand for diabetic gastroparesis treatment.

A notable trend in the diabetic gastroparesis treatment market is the development of new medications. Major companies are actively engaged in creating innovative products to maintain their market positions. In June 2023, the U.S. Food and Drug Administration approved two medications, Empagliflozin (Jardiance) and Synjardy (Empagliflozin and Metformin Hydrochloride), for treating type 2 diabetes in children aged ten and older. This approval marks a significant advancement in diabetes treatment, offering more comprehensive blood sugar management.

Strategic alliances are a key focus for major companies in the diabetic gastroparesis treatment market to enhance their market positions. For instance, in August 2021, Fitbit, a U.S.-based consumer electronics company, entered into an agreement with LifeScan, a U.S.-based diagnostic systems manufacturer in the diabetes market. This alliance aimed to link health tracking apps with glucose monitoring devices, providing diabetes patients access to the OneTouch Reveal app. The integration allows users to sync OneTouch blood glucose data with metrics collected by Fitbit, offering a holistic approach to diabetes management.

Major companies operating in the diabetic gastroparesis treatment market report are Cardinal Health Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, GlaxoSmithKline plc, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kimberly-Clark Corporation, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Allergan Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC

North America was the largest region in the diabetic gastroparesis treatment market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diabetic gastroparesis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The diabetic gastroparesis treatment market consists of revenues earned by entities by providing services such as medical evaluation, medication management, dietary consultation, insulin adjustment, lifestyle modifications, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic gastroparesis treatment market also includes sales of metoclopramide, erythromycin, domperidone, promethazine, and ondansetron (Zofran). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Gastroparesis Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic gastroparesis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic gastroparesis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic gastroparesis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Treatment: Medication; Surgery
• 2) By Route Of Administration: Oral; Injectables
• 3) By Indication: Compensated Gastroparesis; Gastric Failure
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Companies Mentioned: Cardinal Health Inc.; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Ipca Laboratories Ltd.; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Gastroparesis Treatment Market Characteristics

3. Diabetic Gastroparesis Treatment Market Trends And Strategies

4. Diabetic Gastroparesis Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Diabetic Gastroparesis Treatment Market Size and Growth

• 5.1. Global Diabetic Gastroparesis Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Diabetic Gastroparesis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Diabetic Gastroparesis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Diabetic Gastroparesis Treatment Market Segmentation

• 6.1. Global Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medication
• Surgery
• 6.2. Global Diabetic Gastroparesis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Injectables
• 6.3. Global Diabetic Gastroparesis Treatment Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Compensated Gastroparesis
• Gastric Failure
• 6.4. Global Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users

7. Diabetic Gastroparesis Treatment Market Regional And Country Analysis

• 7.1. Global Diabetic Gastroparesis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Diabetic Gastroparesis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Diabetic Gastroparesis Treatment Market

• 8.1. Asia-Pacific Diabetic Gastroparesis Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Diabetic Gastroparesis Treatment Market

• 9.1. China Diabetic Gastroparesis Treatment Market Overview
• 9.2. China Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Diabetic Gastroparesis Treatment Market

• 10.1. India Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Diabetic Gastroparesis Treatment Market

• 11.1. Japan Diabetic Gastroparesis Treatment Market Overview
• 11.2. Japan Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Diabetic Gastroparesis Treatment Market

• 12.1. Australia Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Diabetic Gastroparesis Treatment Market

• 13.1. Indonesia Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Diabetic Gastroparesis Treatment Market

• 14.1. South Korea Diabetic Gastroparesis Treatment Market Overview
• 14.2. South Korea Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Diabetic Gastroparesis Treatment Market

• 15.1. Western Europe Diabetic Gastroparesis Treatment Market Overview
• 15.2. Western Europe Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Diabetic Gastroparesis Treatment Market

• 16.1. UK Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Diabetic Gastroparesis Treatment Market

• 17.1. Germany Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Diabetic Gastroparesis Treatment Market

• 18.1. France Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Diabetic Gastroparesis Treatment Market

• 19.1. Italy Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Diabetic Gastroparesis Treatment Market

• 20.1. Spain Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Diabetic Gastroparesis Treatment Market

• 21.1. Eastern Europe Diabetic Gastroparesis Treatment Market Overview
• 21.2. Eastern Europe Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Diabetic Gastroparesis Treatment Market

• 22.1. Russia Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Diabetic Gastroparesis Treatment Market

• 23.1. North America Diabetic Gastroparesis Treatment Market Overview
• 23.2. North America Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Diabetic Gastroparesis Treatment Market

• 24.1. USA Diabetic Gastroparesis Treatment Market Overview
• 24.2. USA Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Diabetic Gastroparesis Treatment Market

• 25.1. Canada Diabetic Gastroparesis Treatment Market Overview
• 25.2. Canada Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Diabetic Gastroparesis Treatment Market

• 26.1. South America Diabetic Gastroparesis Treatment Market Overview
• 26.2. South America Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Diabetic Gastroparesis Treatment Market

• 27.1. Brazil Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Diabetic Gastroparesis Treatment Market

• 28.1. Middle East Diabetic Gastroparesis Treatment Market Overview
• 28.2. Middle East Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Diabetic Gastroparesis Treatment Market

• 29.1. Africa Diabetic Gastroparesis Treatment Market Overview
• 29.2. Africa Diabetic Gastroparesis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Diabetic Gastroparesis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Diabetic Gastroparesis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Diabetic Gastroparesis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Gastroparesis Treatment Market Competitive Landscape
• 30.2. Diabetic Gastroparesis Treatment Market Company Profiles
  • 30.2.1. Cardinal Health Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Ipca Laboratories Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Abbott Laboratories
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Diabetic Gastroparesis Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. AstraZeneca plc
• 31.3. Medtronics plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Kimberly-Clark Corporation
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Janssen Global Services LLC
• 31.9. Boston Scientific Corporation
• 31.10. Fresenius Kabi AG
• 31.11. Bausch Health Companies Inc.
• 31.12. Allergan Inc.
• 31.13. Salix Pharmaceuticals Inc.
• 31.14. Ironwood Pharmaceuticals Inc.
• 31.15. Wockhardt Ltd.

32. Global Diabetic Gastroparesis Treatment Market Competitive Benchmarking

33. Global Diabetic Gastroparesis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Diabetic Gastroparesis Treatment Market

35. Diabetic Gastroparesis Treatment Market Future Outlook and Potential Analysis

• 35.1 Diabetic Gastroparesis Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Diabetic Gastroparesis Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Diabetic Gastroparesis Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer